Featured
-
-
Article |
Tumour-associated macrophages and Schwann cells promote perineural invasion via paracrine loop in pancreatic ductal adenocarcinoma
- Bin Zhang
- , Xiaofeng Guo
- & Quanbo Zhou
-
Article
| Open AccessEfficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
- Jung Hyun Jo
- , Yong-Tae Kim
- & Si Young Song
-
Article
| Open AccessAnti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis
- Maren Juliane Egidi
- , Sebastian Krug
- & Heidi Griesmann
-
Article
| Open AccessChromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28
- Shujun Zhang
- , Peilong Li
- & Chuanxin Wang
-
Article
| Open AccessTPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
- Michael Guenther
- , Sai Agash Surendran
- & Steffen Ormanns
-
Article
| Open AccessThe impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study
- Lewis A. Hall
- , Siobhan C. McKay
- & Melissa Zhao
-
Article |
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma
- Lucy X. Ma
- , Yifan Wang
- & Grainne M. O’Kane
-
Article |
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
- Kumiko Umemoto
- , Yu Sunakawa
- & Chigusa Morizane
-
Article |
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer
- Zhao Liu
- , Hiromitsu Hayashi
- & Hideo Baba
-
Article |
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
- Giulia Orsi
- , Alessandro Cavaliere
- & Michele Reni
-
Article |
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer
- Geny Piro
- , Carmine Carbone
- & Giampaolo Tortora
-
Review Article |
The application of single-cell sequencing in pancreatic neoplasm: analysis, diagnosis and treatment
- Gaoyuan Lv
- , Liang Zhang
- & Qiushi Tang
-
Article
| Open AccessESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour–stromal IL-1β/NF–κB/ESE3 signalling axis
- Tiansuo Zhao
- , Di Xiao
- & Jihui Hao
-
Article |
Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohorts
- Xiao Luo
- , Wanshui Yang
- & Xuehong Zhang
-
Article |
Lifestyle, body mass index, diabetes, and the risk of pancreatic cancer in a nationwide population-based cohort study with 7.4 million Korean subjects
- Byung Kyu Park
- , Jeong Hun Seo
- & Jung Kyu Choi
-
Article |
Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study
- Citadel J. Cabasag
- , Melina Arnold
- & Isabelle Soerjomataram
-
Review Article |
Circulating tumour DNA: a challenging innovation to develop “precision onco-surgery” in pancreatic adenocarcinoma
- Daniel Pietrasz
- , Elisabetta Sereni
- & Claudio Bassi
-
Article |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
- Sonia Zaibet
- , Vincent Hautefeuille
- & Simon Pernot
-
Article |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
- Yung-Yeh Su
- , Yen-Feng Chiu
- & Li-Tzong Chen
-
Article |
Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5
- Kosei Nakajima
- , Yoshinori Ino
- & Nobuyoshi Hiraoka
-
Article |
Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials
- Daniel Pietrasz
- , Shufang Wang-Renault
- & Pierre Laurent-Puig
-
Article |
The oral microbiome in relation to pancreatic cancer risk in African Americans
- Jessica L. Petrick
- , Jeremy E. Wilkinson
- & Julie R. Palmer
-
Editorial |
Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach
- Ganesh Radhakrishna
- & Paula Ghaneh
-
Article |
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort
- Edouard Auclin
- , Lysiane Marthey
- & Julien Taieb
-
Correspondence
| Open AccessReply to Comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”
- Christopher M. Jones
- , Ganesh Radhakrishna
- & Somnath Mukherjee
-
Article
| Open AccessCirculating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer
- Frances Willenbrock
- , Catrin M. Cox
- & Somnath Mukherjee
-
Article
| Open AccessSuppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5
- Eric D. Young
- , Sharon J. Manley
- & Danny R. Welch
-
Review Article
| Open AccessAutophagy as a therapeutic target in pancreatic cancer
- Max Piffoux
- , Erwan Eriau
- & Philippe A. Cassier
-
Article
| Open AccessBacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
- Michael Guenther
- , Michael Haas
- & Steffen Ormanns
-
Article
| Open AccessComplete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
- Charles R. Dunlop
- , Yann Wallez
- & Duncan I. Jodrell
-
Consensus Statement
| Open AccessConsiderations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position
- Christopher M. Jones
- , Ganesh Radhakrishna
- & Somnath Mukherjee
-
Article
| Open AccessNeoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
- Changhoon Yoo
- , Sang Soo Lee
- & Song Cheol Kim
-
Article
| Open AccessScheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
- P. G. Corrie
- , W. Qian
- & D. I. Jodrell
-
Article
| Open AccessAnti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
- Takahiko Nishigaki
- , Tsuyoshi Takahashi
- & Tetsuji Naka
-
Article
| Open AccessPhase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
- Robin M. J. M. van Geel
- , Emilie M. J. van Brummelen
- & Jan H. M. Schellens
-
Article
| Open AccessTG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial
- Daniel H. Palmer
- , Juan W. Valle
- & Svein Dueland
-
Article
| Open AccessPreoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients
- Shiwei Guo
- , Xiaohan Shi
- & Gang Jin
-
Editorial |
Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
- Maeve A. Lowery
-
Article
| Open AccessPlatinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
- Max M. Wattenberg
- , Daniella Asch
- & Kim A. Reiss
-
Brief Communication
| Open AccessAntihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study
- Jakob Kirkegård
- , Frank Viborg Mortensen
- & Deirdre Cronin-Fenton
-
Article
| Open AccessMulti-omic molecular comparison of primary versus metastatic pancreatic tumours
- Gagandeep Brar
- , Edik M. Blais
- & Michael J. Pishvaian
-
Article
| Open AccessZEB1 and IL-6/11-STAT3 signalling cooperate to define invasive potential of pancreatic cancer cells via differential regulation of the expression of S100 proteins
- Qais Al-Ismaeel
- , Christopher P. Neal
- & Marina Kriajevska
-
Article
| Open AccessFamily history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk
- Tsuyoshi Hamada
- , Chen Yuan
- & Brian M. Wolpin
-
Article
| Open AccessDirect therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
- Mei Gao
- , Miranda Lin
- & Joseph Kim
-
Article
| Open AccessTumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
- Philipp Lohneis
- , Marianne Sinn
- & Anja Jühling
-
Clinical Study
| Open AccessA phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
- Natalie Cook
- , Bristi Basu
- & Duncan Jodrell
-
Clinical Study
| Open AccessKRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study
- Yutaka Nakano
- , Minoru Kitago
- & Yuko Kitagawa
-
Translational Therapeutics
| Open AccessMTOR inhibitor-based combination therapies for pancreatic cancer
- Zonera Hassan
- , Christian Schneeweis
- & Günter Schneider
-
Molecular Diagnostics
| Open AccessCadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma
- Carole Siret
- , Aurélie Dobric
- & Frédéric André